We certainly are very underpriced for a company about to embark on 3 simultaneous and unique trials for a single molecule. Not a fan of technical trading or technical analysis in this space. No tech chart of 6 months or even 3 months ago could predict what-where we are today. That said, does anyone really think the institutions that bought in as part of the Russell and continue to accumulate would allow this company, its stock price and its potential to drop out of the Russell? No way. It will move north to at least cover the listing requirement. Shorts may be in control but suspect it’s short term < 1 year. GLTA longs, believers, the company and those afflicted.
News 
Market Data 
Discover 
